272 related articles for article (PubMed ID: 29093263)
1. Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.
Payne RO; Silk SE; Elias SC; Miura K; Diouf A; Galaway F; de Graaf H; Brendish NJ; Poulton ID; Griffiths OJ; Edwards NJ; Jin J; Labbé GM; Alanine DG; Siani L; Di Marco S; Roberts R; Green N; Berrie E; Ishizuka AS; Nielsen CM; Bardelli M; Partey FD; Ofori MF; Barfod L; Wambua J; Murungi LM; Osier FH; Biswas S; McCarthy JS; Minassian AM; Ashfield R; Viebig NK; Nugent FL; Douglas AD; Vekemans J; Wright GJ; Faust SN; Hill AV; Long CA; Lawrie AM; Draper SJ
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093263
[TBL] [Abstract][Full Text] [Related]
2. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
3. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
[TBL] [Abstract][Full Text] [Related]
4. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Collins KA; Ewer KJ; Spencer AJ; Williams AR; Halstead FD; Moretz SE; Miura K; Epp C; Dicks MD; Poulton ID; Lawrie AM; Berrie E; Moyle S; Long CA; Colloca S; Cortese R; Gilbert SC; Nicosia A; Hill AV; Draper SJ
Mol Ther; 2011 Dec; 19(12):2269-76. PubMed ID: 21862998
[TBL] [Abstract][Full Text] [Related]
5. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
6. APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 Induces
Bjerkan L; Visweswaran GRR; Gudjonsson A; Labbé GM; Quinkert D; Pattinson DJ; Spång HCL; Draper SJ; Bogen B; Braathen R
Front Immunol; 2021; 12():720550. PubMed ID: 34733274
[TBL] [Abstract][Full Text] [Related]
7. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
[TBL] [Abstract][Full Text] [Related]
8. Poor CD4
Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
Front Immunol; 2021; 12():732667. PubMed ID: 34659219
[No Abstract] [Full Text] [Related]
9. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
[TBL] [Abstract][Full Text] [Related]
11. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.
Ord RL; Caldeira JC; Rodriguez M; Noe A; Chackerian B; Peabody DS; Gutierrez G; Lobo CA
Malar J; 2014 Aug; 13():326. PubMed ID: 25135070
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
[TBL] [Abstract][Full Text] [Related]
13. Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults.
Silk SE; Kalinga WF; Mtaka IM; Lilolime NS; Mpina M; Milando F; Ahmed S; Diouf A; Mkwepu F; Simon B; Athumani T; Rashid M; Mohammed L; Lweno O; Ali AM; Nyaulingo G; Mwalimu B; Mswata S; Mwamlima TG; Barrett JR; Wang LT; Themistocleous Y; King LDW; Hodgson SH; Payne RO; Nielsen CM; Lawrie AM; Nugent FL; Cho JS; Long CA; Miura K; Draper SJ; Minassian AM; Olotu AI
Med; 2023 Oct; 4(10):668-686.e7. PubMed ID: 37572659
[TBL] [Abstract][Full Text] [Related]
14. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ
PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
[TBL] [Abstract][Full Text] [Related]
16. Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.
Willcox AC; Huber AS; Diouf A; Barrett JR; Silk SE; Pulido D; King LDW; Alanine DGW; Minassian AM; Diakite M; Draper SJ; Long CA; Miura K
Cell Rep Med; 2021 Jul; 2(7):100326. PubMed ID: 34337556
[TBL] [Abstract][Full Text] [Related]
17. Plasmodium falciparum Cysteine-Rich Protective Antigen (CyRPA) Elicits Detectable Levels of Invasion-Inhibitory Antibodies during Natural Infection in Humans.
Mian SY; Somanathan A; Chaddha K; Pandey AK; Singh H; Krishna S; Chaturvedi N; Uchoi S; Shukla MM; Bharti PK; Singh N; Chauhan VS; Gaur D
Infect Immun; 2022 Jan; 90(1):e0037721. PubMed ID: 34694918
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
[TBL] [Abstract][Full Text] [Related]
19. Functional Comparison of Blood-Stage
Illingworth JJ; Alanine DG; Brown R; Marshall JM; Bartlett HE; Silk SE; Labbé GM; Quinkert D; Cho JS; Wendler JP; Pattinson DJ; Barfod L; Douglas AD; Shea MW; Wright KE; de Cassan SC; Higgins MK; Draper SJ
Front Immunol; 2019; 10():1254. PubMed ID: 31214195
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.
de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S
Front Immunol; 2021; 12():694759. PubMed ID: 34335606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
